Vigil Cash And Equivalents from 2010 to 2024
| VIGL Stock | USD 2.30 0.10 4.55% |
Check Vigil Neuroscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vigil Neuroscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 379.1 K, Interest Expense of 85.2 K or Selling General Administrative of 17.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.18. Vigil financial statements analysis is a perfect complement when working with Vigil Neuroscience Valuation or Volatility modules.
Vigil | Cash And Equivalents |
About Vigil Neuroscience Financial Statements
Vigil Neuroscience investors utilize fundamental indicators, such as Cash And Equivalents, to predict how Vigil Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Vigil Neuroscience, Inc. operates as a subsidiary of Amgen Inc. Vigil Neuroscience operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 48 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Vigil Neuroscience Correlation against competitors. For more information on how to buy Vigil Stock please use our How to buy in Vigil Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vigil Neuroscience. If investors know Vigil will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vigil Neuroscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.07) | Return On Assets (0.40) | Return On Equity (0.70) |
The market value of Vigil Neuroscience is measured differently than its book value, which is the value of Vigil that is recorded on the company's balance sheet. Investors also form their own opinion of Vigil Neuroscience's value that differs from its market value or its book value, called intrinsic value, which is Vigil Neuroscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vigil Neuroscience's market value can be influenced by many factors that don't directly affect Vigil Neuroscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vigil Neuroscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vigil Neuroscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vigil Neuroscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.